Santen Pharmaceutical Co., Ltd. Financial Performance and Outlook Year Ended March 31, 2005

Summary of Year Ended March 2005; Progress of 2003-2005 Medium-term Management Plan; Returning Profit to Shareholders; and Corporate Governance


> May 10, 2005 Takakazu Morita President and CEO

[A Caution Concerning Forward-Looking Statements]

Forecasts of future business results are based on the judgment of the management of Santen using information currently available. Actual results may differ materially from forecasts due to a number of factors, including but not limited to changes in the business environment, launch of new products, fluctuations in exchange rates and changes in related laws and regulations.



Consolidated Sales and Profit



Year Ended March 2005 – Achievements

• Restoration of Profitability

Japan:

- Maintained/increased sales of priority ophthalmic areas (cornea, glaucoma and allergy) and anti-rheumatic drugs; started sales of the glaucoma treatment Rescula Eye Drops; cost reduction and business process reengineering
- OTC Completed adjustment of trade inventory level; improved efficiency of selling expense
- Medical device Concentrated resources on IOL business

Overseas: Turned US ophthalmic business profitable; Increased sales in Europe and Asia


Accelerating New Product Development

Development of focus new product candidates (2 glaucoma, 1 dry eye, 1 antirheumatic) is on or ahead of schedule

Reinforcement of Organizational Strength
 Made decision to enhance corporate governance system



Consolidated Forecast for Year Ending March 2006



2003-2005 Medium-term Management Plan

Basic Objectives		
Restoration of Profitability	Strengthening of R&D	Reinforcement of Organizational Strength
Focus Tasks		
 Early profitability of U.S. operations Expense reduction 	 Accelerate new product development 	 Strengthen corporate governance
 Maintain and improve our domestic earnings base 	 Enhance new product pipeline through focused resource allocation 	 Employee education and enhancement of organizational management capabilities



Status of Medium-term Plan Objectives: Restoration of Profitability

	<u>Year ended</u> <u>March 2004</u> <u>Actual</u>	<u>Year ended</u> <u>March 2005</u> <u>Actual</u>	<u>Year ending</u> <u>March 2006</u> <u>Plan</u>
Early profitability of U.S. of 1. U.S. ophthalmics	operations Dec 03 Sales partnership	Turned profitable (before R&D expenses)	Enhance
Reduction of expenses 2. Manufacturing cost	Introduced new bottles	Completed shift to new bottles	Additional measures
 3 Reform of sales offices - Reform of purchasing - Reform of business 	 Majority of sales offices relocated Introduced e-purchasing system 	 Completed relocation of all sales offices Transition of subject items to online purchase underway 	- Full contribution - Full contribution
Support Maintenance and improve earnings base		- Formulated plans	- Implement
4. Improve MR productivity	Installed MR activity support IT system	Conducted trial to improve customer segmentation and doctor targeting	Full-scale implementation
5. OTC business		Analyze cost structure and devise reform plans les & marketing planning und	Implement cost structure reform plans derway. 6

Completed Shift to New Eye Drop Container Dimple Bottles

- Easy identification: Large, color-coded caps; clear display of product names
- Easy to use:

Dimple – an easy grip; squeezability; slit window allowing users to see the remaining volume in the bottle







Status of Medium-term Plan Objectives:

Strengthening of R&D and Reinforcement of Organizational Strength

Strengthening of R&D	Year ended March 2004 Actual	<u>Year ended</u> <u>March 2005</u> <u>Actual</u>	<u>Year ending</u> <u>March 2006</u> <u>Plan</u>
6. Accelerate new product development	Increase clinical development staff and process reform (glaucoma, cornea and RA)	Shortened pre-clinical period (New policy formulated)	Shorten clinical trials to 5 years and non-clinical studies to 1.5 years (for prioritized projects)
7. Enhance R&D pipeline	investment in promising themesEnhance ophthalmic discovery research	Increase the number of next-generation drug candidates (glaucoma, retina, dry eye and anti- inflammatory)	Bring 2 candidates to clinical study in about one year
Reinforcement of Organizat	<u>tional Strength</u>		
8. Strengthen corporate governance	 External Director elected Shortened term of Directors (2 years to 1 	Continue	 Increase number of Board members (Add 2 outside and 1 internal Directors) Add new committees
9. Employee education and enhancement of organizational manage- ment capabilities	- Continue managemer development program		Continue
Santen			8

Major New Drug Candidates (as of May 2005; < > shows status of May 2004)

1) Ciclosporin DE-076 (in-licensed)	Vernal kerato- conjunctivitis	Immunosuppressant	NDA filed	NDA filed
2) MD-14 IOL (original)	_	Acrylic intraocular lens for cataract surgery	Japan: applied Aug 04 US: Clinical study	applied
3) Tafluprost DE-085 (original)	Glaucoma and ocular hypertension	Prostanoid FP receptor agonist Promotes uveoscleral outflow	Japan: P3 US & Europe: P3	NDA planned 3Q 06FY
4) Olmesartan DE-092 (in-licensed)	Glaucoma and ocular hypertension	Angitotensin II AT ₁ receptor antagonist Promotes uveoscleral outflow	Japan: P2b <p2a> US & Europe: P2 dose finding study</p2a>	1Q FY08
5) Diquafosol tetrasodium DE-089 (in-licensed)	Dry eye	P2Y ₂ receptor agonist Stimulates tear secretion	Japan: P2b <p2a></p2a>	3Q FY08
6) <i>Undetermined</i> DE-096 (original)	Rheumatoid arthritis	Inhibit production of TNF-alpha	Japan: P2a <p1></p1>	_


Key Goals of Year Ending March 2006

- The year ending March 2006 is the final (third) year of our "2003-2005 Medium-term Management Plan." Santen will continue working on the tasks shown on slides 6 and 8 to achieve the Plan's three basic objectives: restoration of profitability; strengthening of R&D; and reinforcement of organizational capabilities.
- The next medium-term goals are: to continue improvements in efficiency; and to prepare for future growth stimulated by new products currently in development.



Returning Profit to Shareholders

- Performance-based return of profits to shareholders
- Maintain and improve the level of cash dividends, considering the future demand of fund and financial forecasts
- Buyback and retirement of shares as an agile means of improving shareholder value and capital efficiency



Reinforcement of Corporate Governance

- Continue the corporate auditor system
- Board of Directors: 5 internal and 3 outside directors (increase 1 internal and 2 outside members)
- Committees: establish Corporate Strategy Committee and Nominating Committee; continue Executive Compensation Committee

